Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTANA: Spartalizumab + mDCF and radiotherapy in metastatic anal squamous cell carcinoma
2024-516005-23-00Phase 2Completed
- Sponsor
- CHRU Nancy
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in anal squamous cell carcinoma (SCCA), sponsored by CHRU Nancy. Primary endpoint: Progression-free survival rate at 1 year. Started Aug 2024; status: completed.
02
Drugs
spartalizumab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2024-516005-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516005-23-00.